Search research articles
Contact Us
Filters
Showing results (71-80 of 125) with videos related to
Page
of 13
Sort By:
CNS Drugs
|
November 4, 2022
Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder"
Azmi Nasser, Joseph T Hull, Tesfaye Liranso, et al.
Paediatric Drugs
|
September 15, 2021
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
European Child & Adolescent Psychiatry
|
September 28, 2021
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 27, 2013
Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration
Jeffrey H Newcorn, Mark A Stein, Ann C Childress, et al.
American Journal of Hypertension
|
March 19, 2015
N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study
Julie K Bower, Mariana Lazo, Kunihiro Matsushita, et al.
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
Maximum entropy model reveals frequent brain state switching in a multiversal brain function analysis in early psychoses
Nicholas Theis, Jonathan Rubin, Ella O'Rourke, et al.
Brain and Behavior
|
February 27, 2023
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree<sup>®</sup> ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
WMJ : Official Publication of the State Medical Society of Wisconsin
|
October 27, 2022
Analysis of Emergency Department Patient-Visit Volumes in an Academic Health System During a COVID-19 Pandemic Statewide 'Safer at Home' Order
Morgan D Wilbanks, Nicole Fumo, Jamie M Aranda, et al.
CNS Drugs
|
March 26, 2026
Correction: An Open‑Label Extension Study Assessing the Long‑Term Safety and Efficacy of Viloxazine Extended‑Release Capsules in Adults with Attention‑Deficit/Hyperactivity Disorder
Ann Childress, Andrew J Cutler, Lenard A Adler, et al.
The Journal of Clinical Psychiatry
|
May 28, 2026
Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial
Lenard A Adler, V Rose Lieberman, Leslie Brijbasi, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 125) with videos related to
Sort By:
Page
of 13
CNS Drugs
|
November 4, 2022
Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder"
Azmi Nasser, Joseph T Hull, Tesfaye Liranso, et al.
Paediatric Drugs
|
September 15, 2021
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
European Child & Adolescent Psychiatry
|
September 28, 2021
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 27, 2013
Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration
Jeffrey H Newcorn, Mark A Stein, Ann C Childress, et al.
American Journal of Hypertension
|
March 19, 2015
N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study
Julie K Bower, Mariana Lazo, Kunihiro Matsushita, et al.
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
Maximum entropy model reveals frequent brain state switching in a multiversal brain function analysis in early psychoses
Nicholas Theis, Jonathan Rubin, Ella O'Rourke, et al.
Brain and Behavior
|
February 27, 2023
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree<sup>®</sup> ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
WMJ : Official Publication of the State Medical Society of Wisconsin
|
October 27, 2022
Analysis of Emergency Department Patient-Visit Volumes in an Academic Health System During a COVID-19 Pandemic Statewide 'Safer at Home' Order
Morgan D Wilbanks, Nicole Fumo, Jamie M Aranda, et al.
CNS Drugs
|
March 26, 2026
Correction: An Open‑Label Extension Study Assessing the Long‑Term Safety and Efficacy of Viloxazine Extended‑Release Capsules in Adults with Attention‑Deficit/Hyperactivity Disorder
Ann Childress, Andrew J Cutler, Lenard A Adler, et al.
The Journal of Clinical Psychiatry
|
May 28, 2026
Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial
Lenard A Adler, V Rose Lieberman, Leslie Brijbasi, et al.
Page
of 13